Is Your Patient Fit or Unfit for Intensive Therapy?
To continue, select another chapter from the Chapter List
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
Determining fitness for intensive therapy can be challenging to assess in patients with AML. In this activity, Dr. Kendra Sweet describes best practice in assessing fitness for intensive therapy for patients with newly diagnosed AML, the impact of comorbidities, and the available tools that should be utilized to determine a patient's fitness for intensive therapy. She will describe appropriate intensive and non-intensive treatment options for patients with AML based on their fitness.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Describe the current role of fitness in determining eligibility for intensive versus non-intensive treatment options in patients with AML
- Evaluate AML patient fitness into clinical practice to aid in decision making and determine an appropriate level of care
- Recognize appropriate therapeutic options for patients with AML based on fitness and other patient and disease characteristics
Is Your Patient Fit or Unfit for Intensive Therapy? – Kendra Sweet, MD, MS
Instructions for Participation and Credit
This activity is eligible for credit through February 17, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Kendra Sweet, MD, MS
Department of Oncologic Sciences
College of Medicine
University of South Florida
Dr. Kendra Sweet received her medical degree from Virginia Commonwealth University School of Medicine, Richmond, and her masters of medical science in clinical and translational research from the University of South Florida, Tampa. She completed an internship and residency in internal medicine from the University of Arizona, and a fellowship in hematology and medical oncology from the University of South Florida. In addition, Dr. Sweet is a registered dietitian. She is an Associate Professor in the Department of Oncologic Sciences, College of Medicine, at the University of South Florida.
Dr. Sweet is American Board of Internal Medicine certified in medical oncology and internal medicine. She is a member of the European Hematology Association, European School of Hematology, American Society of Hematology, American Society of Clinical Oncology, and the American Medical Association. Dr. Sweet's clinical interests include myeloid malignancies with a particular focus on acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, Helsinn, and Jazz Pharmaceuticals.
©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-004-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Kendra Sweet has received honoraria related to formal advisory activities from Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Novartis AG, and Takeda Oncology, and consultant fees from Stemline Therapeutics, Inc.. She has received grant support related to research activities from Incyte Corporation.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
- Chapter 1: Pretest
- Chapter 2: Is Your Patient Fit or Unfit for Intensive Therapy?
- Assessment and Evaluation